Drugs / EXLINKIBART
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT05075993 | Nov 2021 → Feb 2027 expected | esophageal cancer, gastric cancer, head and neck carcinoma, hepatocellular carcinoma +4 | M.D. Anderson Cancer Center | Active not recruiting | No outcome recorded |
| Phase 1 | NCT04694781 | May 2021 → Oct 2023 | cancer | Lyvgen Biopharma Holdings Limited | Completed | No outcome recorded |
| Phase 1 | NCT04130542 | Oct 2019 → Dec 2025 | cancer | Lyvgen Biopharma Holdings Limited | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05301764 | May 2022 → Dec 2025 | soft tissue sarcoma | Lyvgen Biopharma Holdings Limited | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06378177 | Jun 2024 → Oct 2027 expected | head and neck squamous cell carcinoma | Lyvgen Biopharma Holdings Limited | Active not recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EXLINKIBART | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314677 ↗ |
| Known as | LVGN6051 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04130542 ↗ |
| Action | Activate | “acts as an agonist against CD137” NCT04130542 ↗ |
| Modality | Monoclonal antibody | “LVGN6051 is a humanized monoclonal antibody” NCT04130542 ↗ |
| Route | Intravenous | “Route of administration is IV infusion” NCT04130542 ↗ |